You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK):Coherus已啟動行使JS006選擇權的程序

格隆匯1月11日丨君實生物(01877.HK)發佈公吿,有關與Coherus訂立的許可與商業化協議。2022年1月10日,Coherus已啟動行使JS006選擇權的程序,以獲得許可在美國和加拿大(“Coherus區域”)內開發JS006或含有JS006的任何產品用於治療或預防人類疾病。在遵守適用法律及滿足雙方書面約定的條件的前提下,按照許可與商業化協議,Coherus將向公司一次性支付3500萬美元執行費,款項不可退回;在達到規定的里程碑事件後,Coherus將向公司支付累計不超過2.55億美元的里程碑款,外加任何包含JS006產品在Coherus區域內年銷售淨額18%的銷售分成。預計交易將在適用法律要求的政府手續完畢後完成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account